课题基金 / 基金详情

Early Detection of Ovarian Cancer Through Epigenetic Factors in the WHI

Early Detection of Ovarian Cancer Through Epigenetic Factors in the WHI
通过 WHI 中的表观遗传因素早期发现卵巢癌
批准号:
9240606
负责人:
JEANINE M. GENKINGER
金额:
$57.23万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-03-08 至 2021-02-28

项目摘要

项目成果

JEANINE M. GENKINGER的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):卵巢癌是美国女性癌症死亡的第五大原因;62%的病例被诊断为晚期,只有27%的病例存活了5年以上。然而,当卵巢癌在局限性阶段被发现时(15%的病例),5年生存率为94%。由于如果及早诊断可以显著提高存活率,因此通过加强风险评估来改进早期发现的方法至关重要,从而实现更有针对性的初级预防和筛查。Rosner和Pfeiffer的两个经过验证的风险评估模型识别出卵巢癌风险较高的女性,但只有适度的区分力。目前,尚无有效的卵巢癌筛查方法。以前在平均风险人群中使用CA-125等单一标志物进行筛查的方法都不成功,并导致了许多假阳性结果。确定对早期癌症发生重要的新的标记组合是关键;表观遗传事件(DNA甲基化)被注意到发生在癌症发生的早期,反映了环境侮辱和遗传脆弱性。对游离DNA中DNA甲基化的测量显示出对其他癌症的早期发现和筛查的希望。新出现的证据表明,在组织和血浆中测量的特定基因的DNA甲基化导致检测卵巢癌的敏感性为75%。然而,卵巢癌的所有证据都来自小型横断面或回顾性临床研究,没有流行病学数据或流行病学数据有限,这引发了人们对暂时性和混乱性的担忧。我们建议通过识别一组可以早期发现卵巢癌的DNA甲基化标记来复制和建立这些有希望的发现。利用美国最大的女性健康前瞻性研究之一的妇女健康倡议(WHI),我们将使用高通量靶向重测序方法,验证在肿瘤组织和邻近非肿瘤组织中测量的96个关键基因(由癌症基因组图谱(TCGA)发现)的DNA甲基化差异。从这96个TCGA基因中,我们将确定组织学差异甲基化的前10个基因(n对=200;目标1)。在嵌套病例对照中(n例=610例;目标2),我们将检查血浆中测量的这10个前10个基因的DNA甲基化是否是癌症诊断前几年卵巢癌风险的预测因素。在目标3中,我们将评估DNA甲基化标记物的整体性能,以增强现有的卵巢癌风险模型在准确性、区分性和假阳性方面(n=161,808名妇女)。我们将在一个独立的前瞻性队列中验证我们的发现,乳腺癌家族登记((BCFR);n=11,950个家庭;ncase=164;AIM 4)。WHI和BCFR是实现这些目标的理想研究;这两个研究所都收集了生物检疫和详细的流行病学数据。我们将使用一种新的两级方法来早期检测卵巢癌,该方法检查卵巢癌风险(一级预防)范围内有希望的生物标记物(二级预防)。我们的目标是通过准确识别高危个体和可靠的早期检测标志,减少卵巢癌的假阳性、发病率和死亡率。
英文摘要
DESCRIPTION (provided by applicant): Ovarian cancer is the 5th leading cause of cancer death among US women; 62% of cases are diagnosed at advanced stages in which only 27% survive past 5 years. Yet, when ovarian cancer is detected at the localized stage (15% of cases), the 5 year survival rate is 94%. As survival is drastically improved if diagnosed early, methods to improve early detection through enhanced risk assessment, leading to better targeted primary prevention and screening are critical. The two validated risk assessment models from Rosner and Pfeiffer identify women at higher risk for ovarian cancer, but only have modest discriminatory power. Currently, no effective screening modality exists for ovarian cancer. Previous approaches for screening using single markers such as CA-125 in average risk populations have been unsuccessful, and led to many false positive results. Identifying novel panels of markers important to early carcinogenesis is key; epigenetic events (DNA methylation) are noted to occur early in carcinogenesis and reflect environmental insults and genetic vulnerability. Measurement of DNA methylation in cell free DNA has shown promise for early detection and screening for other cancers. Emerging evidence has shown that DNA methylation of select genes measured in tissue and plasma results in sensitivities >75% for detecting ovarian cancer. Yet, all evidence for ovarian cancer comes from small cross-sectional or retrospective clinical studies with no or limited epidemiologic data, raising concerns about temporality and confounding. We propose to replicate and build upon these promising findings by identifying a panel of DNA methylation markers that can detect ovarian cancer early. Using the Women's Health Initiative (WHI), one of the largest prospective studies in the US for women's health, we will verify differences in DNA methylation of 96 key genes (discovered by The Cancer Genome Atlas (TCGA)) measured in tumor vs. adjacent non tumor tissue using high throughput targeted resequencing. From these 96 TCGA genes, we will identify the top 10 genes that are differentially methylated by histology (npairs=200; Aim 1). In a nested case control (ncases=610; Aim 2), we will examine if DNA methylation of these top 10 genes measured in plasma are predictors of ovarian cancer risk years prior to cancer diagnosis. In Aim 3, we will evaluate the overall performance of DNA methylation markers to enhance existing ovarian cancer risk models in terms of accuracy, discrimination and false positives (n=161,808 women). We will validate our findings in an independent prospective cohort, the Breast Cancer Family Registry ((BCFR); n=11,950 families; ncases=164; Aim 4). The WHI and BCFR are ideal studies to conduct these aims; both have collected biospecimens and detailed epidemiologic data. We will employ a novel two-tiered approach for early detection of ovarian cancer that examines promising biomarkers (secondary prevention) across the spectrum of ovarian cancer risk (primary prevention). Our goal is through accurate identification of high risk individuals and reliable markers of early detection, we will reduce false positives, morbidity and mortality from ovarian cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Coordinating Center for the Program on the Origins of Gastroesophageal Cancers
Coordinating Center for the Program on the Origins of Gastroesophageal Cancers
Institutional Career Development Core
Institutional Career Development Core
海外基金